Windtree Therapeutics INC /DE/ 8-K filings

Windtree Therapeutics has received notices from Nasdaq regarding non-compliance with board independence and audit committee rules, as well as a deficiency due to its stock price falling below the minimum bid price.

Windtree Therapeutics has partnered with New Growth Advisors to explore strategic options, including out-licensing or asset sale, for its cardiovascular portfolio following positive Phase 2 trial results.

Windtree Therapeutics reported positive Phase 2b clinical trial results for istaroxime in cardiogenic shock, secured $13.9 million in funding, and addressed a Nasdaq listing compliance issue.

Windtree Therapeutics has finalized the employment agreement with its newly appointed CFO, Jamie McAndrew, detailing her compensation and termination benefits.

Windtree Therapeutics has announced that Craig Fraser will retire as President and CEO, effective December 1, 2024, and Jed Latkin will succeed him in the role.

Windtree Therapeutics has filed a prospectus supplement to issue up to $27.2 million in common stock under its existing equity line of credit with Seven Knots, LLC.

Windtree Therapeutics sold 790,500 shares of common stock for $1.7 million and converted preferred shares, increasing the total outstanding shares to 3,679,686.

Windtree Therapeutics has appointed Jamie McAndrew as Senior Vice President and Chief Financial Officer, effective September 25, 2024.

Windtree Therapeutics has updated its investor presentation, which will be used in future meetings with investors.

Windtree Therapeutics reports positive topline results from its Phase 2b SEISMiC Extension Study, showing istaroxime significantly improved cardiac function and blood pressure in heart failure patients experiencing early cardiogenic shock.

Windtree Therapeutics reports positive topline results from its Phase 2b SEISMiC Extension Study of istaroxime, showing significant improvement in systolic blood pressure for patients with early cardiogenic shock.

Windtree Therapeutics successfully held its 2024 Annual Meeting of Stockholders, electing four directors and approving several key proposals including executive compensation and share issuances.

Windtree Therapeutics reports the sale of common stock and conversion of preferred shares, resulting in a significant increase in outstanding shares.

Windtree Therapeutics reported its second quarter 2024 financial results, highlighted by progress in its istaroxime clinical trials and recent capital raising activities.

Windtree Therapeutics has announced the resignation of two board members and the appointment of two new independent directors, along with a new lead independent director, all effective August 13, 2024.

Windtree Therapeutics has entered into a securities purchase agreement for a private placement expected to generate approximately $1 million in gross proceeds.

Windtree Therapeutics has entered into a securities purchase agreement for a private placement, raising approximately $12.9 million to be used for working capital and general corporate purposes.

Windtree Therapeutics has entered into agreements to issue senior secured and unsecured notes totaling $200,000 to two institutional investors.

Windtree Therapeutics has updated its investor presentation, which will be used in future meetings with investors.

Windtree Therapeutics has entered into a common stock purchase agreement for up to $35 million and issued a $350,000 convertible promissory note, alongside securing senior secured notes for $350,000.

Windtree Therapeutics has updated its corporate presentation for use in ongoing investor meetings.

Windtree Therapeutics has completed a 1-for-18 reverse stock split, effective April 19, 2024, to maintain Nasdaq listing compliance.

Windtree Therapeutics announced its fourth quarter and year-end 2023 financial results, highlighting progress in clinical programs, strategic acquisitions, and partnerships.

Windtree Therapeutics' stockholders have approved a reverse stock split at a ratio between 1-for-5 and 1-for-25, with the exact ratio and timing to be determined by the Board of Directors.

Windtree Therapeutics has entered into an asset purchase agreement with Varian Biopharmaceuticals and secured $1.5 million through a convertible note offering.

Windtree Therapeutics' Interim CFO, John A. Tattory, has resigned effective February 15, 2024, due to cost-cutting measures, with CEO Craig E. Fraser assuming the role of principal financial officer on an interim basis.

Windtree Therapeutics has engaged Ladenburg Thalmann to evaluate strategic options, including a potential sale or merger, to maximize shareholder value.

Windtree Therapeutics has entered into an agreement with Deerfield Management to terminate milestone payment obligations in exchange for cash and common stock.

Windtree Therapeutics has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing the company at risk of delisting.

Windtree Therapeutics has entered into a licensing agreement with Lees Pharmaceutical for its cardiovascular products in several Asian markets and amended agreements with Philip Morris related to its former pulmonary care platform.